Modulus Oncology

An innovative spin-out company created by a founding team of scientists from The University of Sheffield and successful biotech entrepreneurs. Modulus has developed first-in-class antagonists of a G protein-coupled receptor, the adrenomedullin 2 receptor (AM2R) for the treatment on cancer.